Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation

Inclusion Criteria: 1. Kidney transplant recipients at Washington University/Barnes-Jewish Hospital 2. Experiencing GI toxicity from MPA as determined by the treating physician within 12 months post-renal transplant 3. On standard immunosuppression with tacrolimus and prednisone Exclusion Criteria: 1. Dual organ or kidney after another solid organ transplant 2. Presence of a preexisting significant GI condition that does not have a presumed causal relationship with MPA 3. Evidence of any GI disorder induced by an infection, underlying medical condition, or concomitant medication other than MPA 4. Estimated glomerular filtration rate (eGFR) \<40 ml/min at time of possible conversion 5. Proteinuria \>1 gram/day at time of possible conversion 6. Profound bone marrow suppression at the time of possible conversion as defined as: * Hemoglobin \<10 g/dL * White blood cell (WBC) \< 3 K/cumm * Platelets \<100 K/cumm 7. Wound healing issues at time of possible conversion (eg, wound dehiscence, wound infection, incisional hernia, lymphocele, seroma) 8. Elevated total cholesterol (\>350 mg/dL) and/or triglycerides (\>500 ng/dL) at time of possible conversion 9. Hypersensitivity to everolimus, sirolimus, or other rapamycin derivatives